HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human

Immobilized HLA-A*11:01&B2M&KRAS G12D TCR at 1 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human, His Tag with the EC50 of 53.7 ng/ml determined by ELISA.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human

The purity of HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Z06618
¥208,928.00

Ask us a question
Product Introduction
Species Human
Protein Construction
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer[Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGADGVGK peptide]
Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK		 His Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 258 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human
    • HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human

    Immobilized HLA-A*11:01&B2M&KRAS G12D TCR at 1 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human, His Tag with the EC50 of 53.7 ng/ml determined by ELISA.

  • HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human
    • HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human

    The purity of HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human
    • HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human

    HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.


Background
Target Background Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Synonyms MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.